Tag Archives: PhRMA
By Jill Wechsler | Published: January 21, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: September 7, 2011
A trade group representing the largest pharmacy benefits managers (PBMs) has proposed a way to trim $100 billion in government costs for prescription drugs over 10 years. To the pharmaceutical industry, that trim might look more like a beheading.
By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
By Ben Comer | Published: August 3, 2011
Springtime optimism and the gentle steam of a perceived economic recovery in the US has all but dissipated, with the blanketing heat of deficit politics and a job situation that’s anything but august. In July, the US pharmaceutical industry shed 13,493 jobs, more than any other sector, according to an updated Challenger, Gray & Christmas […]